Wolfgang Miesbach on The 1st Case of Secondary Malignancy Triggered by Integrated AAV
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”Is there evidence that integrated AAV can trigger oncogenesis in a clinical setting?
First case worldwide with molecular evidence linking AAV integration to human malignancy.
The FDA placed clinical holds on REGENXBIO’s AAV9-based gene therapies after detecting a CNS tumour in a 5-year-old with Hurler syndrome (MPS I).
The case:
Patient: 5-year-old with Hurler syndrome (MPS I)
Therapy: RGX-111 — AAV9 carrying IDUA gene (α-L-iduronidase)
Dose: 5.0×10¹⁰ vg/gram brain mass (~10¹³⁻¹⁴ total)
Route: Intracisternal injection (direct CSF)
Timeline: Brain tumour detected 4 years post-injection
Status: Asymptomatic; surgically resected; progressing developmentally
Critical context: No tumours in 9 other RGX-111 recipients or 32 RGX-121-treated patients (some followed ~7 years).
Pathogenic mechanism:
Finding: AAV integration in resected tumour with PLAG1 proto-oncogene overexpression.
Mechanism: PLAG1 (pleomorphic adenoma gene 1) is normally silenced in adult tissues. AAV integration may have created a promoter substitution event—placing the strong CMV/CB7 promoter near PLAG1, driving ectopic overexpression. This recapitulates the exact mechanism in spontaneous PLAG1-driven tumours (salivary adenomas, lipoblastomas).
Context: At clinical doses (~10¹⁴ vector genomes), even 0.1–1% integration frequency equals millions of integration events per patient.
Implications for haemophilia gene therapy:
Haemophilia therapies target the liver (AAV5/AAV8), not CNS (AAV9)—fundamentally different biology.
Evidence from >500 haemophilia patients treated with gene therapy:
8 cancer cases reported total: NO evidence AAV caused the cancer—
Adult hepatocytes are postmitotic; strong regenerative capacity dilutes integrated genomes
AAV5/AAV8 are liver-selective; minimal CNS penetration
This case increases uncertainty and awareness. Patient awareness and informed consent so importannt:
- Detailed baseline information before treatment
- Explicit shared decision-making
- Long-term surveillance protocols and registries”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Mar 18, 2026, 16:34Richard Buka: Exploring the COBRRA Trial in the Latest Episode of Don’t Just Read the Abstract
-
Mar 18, 2026, 16:22Heghine Khachatryan: Navigating the New Era of Hemophilia Gene Therapy
-
Mar 18, 2026, 16:21Georges Chahoud: Top Take-Home Messages from the AHA/ACC/Multisociety Acute PE Guideline
-
Mar 18, 2026, 16:19Cedric Hermans: Unleashing the Potential of Physical Activity in Hemophilia A Patients
-
Mar 18, 2026, 16:17Asif Mushtaq: Managing Cardiac Surgery with Cardiopulmonary Bypass in Hemophilia
-
Mar 18, 2026, 16:15Amir Kraitzer: Engineering Hemocompatible Surfaces to Overcome Thrombosis in Medical Devices
-
Mar 18, 2026, 16:11Hemant Sharma: Advancing Neonatal Care with New Strategies to Prevent IVH
-
Mar 18, 2026, 16:09Yves Bikorimana: How a Simple Temperature Change Can Trigger Antibody-Mediated Destruction of RBCs
-
Mar 18, 2026, 16:07Scott Isaacs: Optimizing Brain Vitality and Slowing Neurodegeneration Through Daily Habits